Update date
15 May 2026
Jyong Biotech Ltd. financial metrics
Period Q4 2025 · Filed 15 May 2026
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
76,027,667
Period-end balance · 31 Dec 2025
|
|
| Common Stock, Shares, Outstanding |
76,028,000
Period-end balance · 31 Dec 2025
|
+3.6% |
| Common Stock, Value, Issued |
$1,000
Period-end balance · 31 Dec 2025
|
0% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Payable, Current |
$2,000
Period-end balance · 31 Dec 2025
|
-33% |
| Accrued Liabilities, Current |
$1,044,000
Period-end balance · 31 Dec 2025
|
-13% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax |
$682,000
Period-end balance · 31 Dec 2025
|
-39% |
| Assets |
$20,778,000
Period-end balance · 31 Dec 2025
|
+226% |
| Assets, Current |
$15,542,000
Period-end balance · 31 Dec 2025
|
+7445% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$1,178,000
Period-end balance · 31 Dec 2025
|
+1066% |
| Common Stock, Par or Stated Value Per Share |
0
Period-end balance · 31 Dec 2025
|
0% |
| Common Stock, Shares Authorized |
5,000,000,000
Period-end balance · 31 Dec 2025
|
0% |
| Common Stock, Shares, Issued |
76,028,000
Period-end balance · 31 Dec 2025
|
+3.6% |
| Deferred Tax Assets, Gross |
$17,103,000
Period-end balance · 31 Dec 2025
|
+0.35% |
| Deferred Tax Assets, Operating Loss Carryforwards |
$6,529,000
Period-end balance · 31 Dec 2025
|
-5.6% |
| Deferred Tax Assets, Valuation Allowance |
$17,103,000
Period-end balance · 31 Dec 2025
|
+0.35% |
| Employee-related Liabilities, Current |
$137,000
Period-end balance · 31 Dec 2025
|
-5.5% |
| Lessee, Operating Lease, Liability, to be Paid |
$109,000
Period-end balance · 31 Dec 2025
|
|
| Lessee, Operating Lease, Liability, to be Paid, Year Four |
$2,000
Period-end balance · 31 Dec 2025
|
|
| Lessee, Operating Lease, Liability, to be Paid, Year One |
$82,000
Period-end balance · 31 Dec 2025
|
|
| Lessee, Operating Lease, Liability, to be Paid, Year Three |
$2,000
Period-end balance · 31 Dec 2025
|
|
| Lessee, Operating Lease, Liability, to be Paid, Year Two |
$23,000
Period-end balance · 31 Dec 2025
|
|
| Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
$2,000
Period-end balance · 31 Dec 2025
|
|
| Liabilities |
$45,684,000
Period-end balance · 31 Dec 2025
|
+6.5% |
| Liabilities and Equity |
$20,778,000
Period-end balance · 31 Dec 2025
|
+226% |
| Liabilities, Current |
$34,810,000
Period-end balance · 31 Dec 2025
|
+187% |
| Operating Lease, Liability |
$107,000
Period-end balance · 31 Dec 2025
|
|
| Operating Lease, Liability, Current |
$81,000
Period-end balance · 31 Dec 2025
|
-49% |
| Operating Lease, Liability, Noncurrent |
$26,000
Period-end balance · 31 Dec 2025
|
+62% |
| Operating Lease, Right-of-Use Asset |
$66,000
Period-end balance · 31 Dec 2025
|
-52% |
| Operating Lease, Weighted Average Discount Rate, Percent |
0.0305
Period-end balance · 31 Dec 2025
|
-4.7% |
| Other Assets, Noncurrent |
$6,000
Period-end balance · 31 Dec 2025
|
0% |
| Other Liabilities, Noncurrent |
$60,000
Period-end balance · 31 Dec 2025
|
+3.4% |
| Property, Plant and Equipment, Gross |
$4,833,000
Period-end balance · 31 Dec 2025
|
+4.5% |
| Property, Plant and Equipment, Net |
$3,088,000
Period-end balance · 31 Dec 2025
|
+1.3% |
| Retained Earnings (Accumulated Deficit) |
$37,751,000
Period-end balance · 31 Dec 2025
|
-14% |
| Stockholders' Equity Attributable to Parent |
$24,906,000
Period-end balance · 31 Dec 2025
|
+32% |
Comparisons, sources and research notes
Sources and sharing
MENS - Jyong Biotech Ltd. Financial Facts
- Context
- Latest metrics period: Q4 2025
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q4 2025
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q4 2025.
- Most recent SEC facts end date on this page: 31 Dec 2025.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for MENS - Jyong Biotech Ltd.
Latest financial period: Q4 2025. Reopen this facts page to verify the newest reported period against the prior baseline.
Page type
Company facts
Latest period
Q4 2025
SEC-backed company facts were refreshed from filings filed on 15 May 2026.
Filing notes and source
Key facts
- MENS - Jyong Biotech Ltd. financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q4 2025.
- Headline metric summary will appear when SEC facts are available.
Change
- No metrics are currently available for comparison on this facts page.
- Changes will populate automatically as new 10-Q/10-K periods are processed.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
DCF estimate is unavailable because required valuation inputs are missing.
Missing: Free cash flow.
Data confidence notes
- Free cash flow unavailable: operating cash flow or capex is missing
- Valuation unavailable: free cash flow is missing
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
n/a
Insufficient Data Confidence low
Financial Health
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first